Review Article
Tailored Extracellular Vesicles: Novel Tool for Tissue Regeneration
Table 5
Modified EVs in the therapy of digestive diseases.
| Diseases | EV Sources | Specific substrates | Modification methods | Modified EVs | Biological effects | Ref. |
| Liver fibrosis | ADSC | miR-122 | Cell transfection | miR-122-EV | Inhibition of liver fibrosis | [113] | Liver fibrosis | Fibroblast-like MSC | SiRNA or ASO targeting STAT3 | Electroporation | SiRNA-EV or ASO-EV | Inhibition of STAT3 expression and ECM deposition | [115] | Liver injury | HEK293T | HuR; antimiR-155 fused with AREs | CD9-HuR fusion protein system | CD9-HuR+antimiR-155-AREs-EV | High encapsulation of antimiR-155; antifibrosis | [116] | IBD | HucMSC | miR-326 | Exo-Fectâ„¢ agent | miR-326-EV | anti-inflammation effects | [120] | IBD | BMSC | HO-1 | Cell transfection | HBM-EV | Anti-inflammation effects | [122] | IBD | Ginger plant | SiRNA-CD98; ginger-derived lipid vehicles | Turbo Fect reagent | GDLV-CD98 | Targeted delivery; lower expression of CD9 | [72] |
|
|